GAUZ vs KALA

Analysts rate KALA BIO, Inc.

(KALA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Gauzy Ltd.

Ordinary Shares (GAUZ) delivered a total return of -96. 9%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: GAUZ returned -96. 9% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Gauzy Ltd.

Ordinary Shares (GAUZ) is the lower-risk stock at 1. 13β versus KALA BIO, Inc. 's 2. 14β — meaning KALA is approximately 90% more volatile than GAUZ relative to the S&P 500. On balance sheet safety, Gauzy Ltd. Ordinary Shares (GAUZ) carries a lower debt/equity ratio of 100% versus 3% for KALA BIO, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: KALA BIO, Inc.

grew EPS 59. 8% year-over-year, compared to 31. 7% for Gauzy Ltd. Ordinary Shares. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gauzy Ltd.

Ordinary Shares (GAUZ) is the more profitable company, earning -51. 4% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps -51. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GAUZ leads at -29. 7% versus -150. 6% for KALA. At the gross margin level — before operating expenses — GAUZ leads at 28. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Gauzy Ltd.

Ordinary Shares (GAUZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13)). KALA BIO, Inc. (KALA) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GAUZ: -96. 9%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GAUZ (Technology) and KALA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GAUZ is a small-cap high-growth stock; KALA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.